RxDoctor Payments Data

Priyanka Gosain, MD

Cardiovascular Disease · Hollywood, FLNPI 1881901882

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,465 of the $4,807 with a category attached, or 72.1%. Alnylam Pharmaceuticals Inc. accounts for 75.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $4,288 and has fallen 93.7% since, to $272 in 2025.

$4,807in general payments, 2019–2025

Across 28 payments — averaging $171.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$4K
  • Abbott$722
  • Pfizer$104
  • E.r. Squibb & Sons, L.L.C.$97
  • Bayer$46
  • AstraZeneca$42
  • plus $166 from 6 others

What the payments were for

  • Consulting fees$3,46572%
  • Travel & lodging$802%
  • Food & beverage$1,21625%
  • Education$461%

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,807 in reported general payments places this provider in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida →

Medicare billing

Part B allowed, 2024
$64,459
Medicare patients
223
Services billed
691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis37$650,088
AdempasRiociguat38$515,225
OpsumitMacitentan37$435,392
VyndaqelTafamidis Meglumine12$304,070
CamzyosMavacamten14$109,798
EntrestoSacubitril/Valsartan78$81,009
FarxigaDapagliflozin Propanediol84$80,053
Tadalafil23$59,687
Everolimus16$36,629
JardianceEmpagliflozin37$31,101
EliquisApixaban23$14,935
Repatha SureclickEvolocumab15$10,837
Tacrolimus58$6,703
Sirolimus17$5,817
Eplerenone39$2,477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$104$969,09272 claims
BayerAdempas$46$515,22538 claims
Actelion Pharmaceuticals US, Inc.Opsumit$32$435,39237 claims
E.r. Squibb & Sons, L.L.C.Camzyos$97$109,79814 claims
AstraZenecaFarxiga$42$80,05384 claims
Boehringer IngelheimJardiance$18$31,10137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Hollywood

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →